Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial

The combination of lenalidomide and low-dose dexamethasone is an effective treatment for multiple myeloma (MM). Addition of alkylating agents to lenalidomide or thalidomide results in increased response rates and deeper responses. We designed this trial to study the combination of cyclophosphamide,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Kumar, Shaji K., Lacy, Martha Q., Hayman, Suzanne R., Stewart, Keith, Buadi, Francis K., Allred, Jacob, Laumann, Kristina, Greipp, Philip R., Lust, John A., Gertz, Morie A., Zeldenrust, Steven R., Bergsagel, P. Leif, Reeder, Craig B., Witzig, Thomas E., Fonseca, Rafael, Russell, Stephen J., Mikhael, Joseph R., Dingli, David, Rajkumar, S. Vincent, Dispenzieri, Angela
Format: Artigo
Idioma:Inglês
Publicat: 2011
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3901994/
https://ncbi.nlm.nih.gov/pubmed/21630308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.22053
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars